Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant Zoster Vaccine (CHO Cell)
- Development stage
- Unknown
- Lead developer
- MAXVAX Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant Zoster Vaccine (CHO Cell) is an investigational recombinant subunit vaccine developed by MAXVAX Biotechnology for the prevention of herpes zoster (shingles) in adults aged 40 years and older. The vaccine utilizes the varicella-zoster virus (VZV) glycoprotein E (gE) as its primary antigen, which is expressed in Chinese Hamster Ovary (CHO) cells. It is formulated with the proprietary MA105 adjuvant system to enhance the immune response. Administered via intramuscular injection in a two-dose schedule (0 and 2 months), the vaccine is currently in Phase III clinical trials in China to evaluate its efficacy, safety, immunogenicity, and lot-to-lot consistency of commercial-scale production batches.
- Other names
- Recombinant Herpes Zoster Vaccine (CHO Cell)MAXVAX Herpes Zoster Vaccine
02
Targets
gE (VZV glycoprotein E)
Beyond the preview
Go deeper on Recombinant Zoster Vaccine (CHO Cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombinant Zoster Vaccine (CHO Cell).